Lecture 4

Registry of HLA epitopes and HLAMatchmaker analysis for antibody-verified epitopes

16th Workshop Project: International HLA Epitope Registry GOALS:

- Develop a notation system for epitopes encoded by HLA-ABC, DRB1/3/4/5, DQAB, DPAB and MICA
- Establish a database of antibody-verified HLA epitopes
- Offer clinically relevant search functions

The registry does not address so-called cellular HLA epitopes defined by alloreactive T-cells

The Website-Based International Registry of Antibody-Verified HLA Epitopes

Int J. Immunogenetics, 40: 54-59

http://www.epregistry.com

Developed and managed by

Marilyn Marrari and Rene Duquesnoy

University of Pittsburgh School of Medicine, Pittsburgh PA and

Luiz Claudio Sousa, Adalberto da Silva, Keylla Maria Aita, Jose Renato Barroso, Mário Sérgio Marroquim and Semiramis do Monte

Federal University of Piaui, Teresina, PI, Brazil

HLA Epitope Registry: www.epregistry.ufpi.br

(can be viewed in Microsoft Internet Explorer, Google Chrome or Mozilla Firefox browsers)

 Website information is for research use only. Users must agree to terms of use before using website:



WEBSITE TERMS OF USE

WEBSITE DISCLAIMER

By using the site, you agree to the following terms of use, which constitute an agreement between the website and you.

These terms may be changed from time to time. You may view the most current version through the link that appears on the bottom of all pages on the website.


- This website is designed for research purposes only. The contents are not intended for making clinical decisions regarding donor selection or patient care.
- The website disclaims any liability whatsoever for any documentation, information, programs, software or other material that is or may become part of the website. We do not warrant or guarantee that the information will not be offensive to any user and/or may not meet your needs and requirements.
- The website may include links to third party Web service providers. These links are provided solely as a convenience to you, and not as an endorsement of the content on such sites. We are not responsible for the content of linked third-party sites.

I have read the Terms of Use shown above and agree with them.

I agree

l Disagree

Registry Home Page



HLA Epitope Registry

♠ Home

Databases

Resources

Contact Us

Description

- > Registration
- New Epitopes
- ABC Database
- > DRB Database
- > DQ Database
- > DP Database
- ➤ MICA Database

Description

This website is designed for research purposes only. The contents are not intended for making clinical decisions regarding donor selection or patient care.

There are five separate databases: ABC, DRB1/3/4/5, DQB + DQA, DPB + DPA and MICA.

Their layouts display:

- Epitope names
- Polymorphic residue descriptions
- 3 Epitope frequencies
- 4 Antibody reactivity descriptions of "confirmed" or "provisional" antibody-defined epitopes
- 5 Information about corresponding "structural" epitopes
- 6 Epitope-carrying alleles in Luminex panels
- Listings of all alleles with antibody-defined epitopes.

Each epitope has its own row and epitopes are sorted according their sequence positions. Under each epitope there are rows for possible variants with distinct molecular configurations. Each epitope database has search options to identify repertoires of antibody-defined epitopes on selected alleles and epitopes that are mismatched for a given HLA type. For more detailed information about the HLA Epitope Registry, click here.

Class I Eplet Examples

Eplet	Description	Eplet-Carrying Alleles in Luminex Panel
62GE	62G,63E,65R	A*02:01/02/03/05/06,B*57:01/03,*58:01
166DG	166D,167G	A*01:01,*23:01,*24:02,*80:01,B*15:12
163EW	162G163E166E167W	A*66:02,B*07:02*13:01/02,*27:05/08,*40:01/02/06,*47:01,*48:01,*73:01,*81:01,C*02:02,*17:01
44KM ₃	43Q44K45M46E / 149A150V151H152A / 158V	A*01:01, A*36:01

Locus	Eplet	Description	Eplet-Carrying Alleles in Luminex Panel
MICA	24T	24T, 26V,36C	A*001,*012,*018
MICA	175S	173E,175S	A*004,*006,*009,*016,*019,*033,*036

Class I ABC Database

Databases

ABC

DRB

DQB + DQA

DPB + DPA

MICA


> Filters

Epitope	Polymorphic Residues	Frequency	Antibody Reactivity	Struct Epitope	Luminex Alleles	All Alleles
163LE	163L166E				B*15:01, B*15:02, B*15:03, B*15:10, B*15 More	A*26:04, B*07:20 B*07:24, B*07:60 B*08 More
163R	163R		Provisional	View	A*01:01, A*11:01, A*11:02, A*25:01, A*26 More	A*01:01, A*01:02 A*01:03, A*01:06 A*01 More
163RD	162G163R166D167G		Confirmed	View	A*01:01 More	A*01:01, A*01:02 A*01:03, A*01:06 A*01 More
163RE	162G163R166E167W		Confirmed	View	A*11:01, A*11:02, A*25:01, A*26:01, A*43 More	A*02:101, A*02:135, A*02:154, A*02:38, A

Antibody Reactivity Report for 163RE

Epitope:	163RE (confirmed)						
Luminex single allele reactivity: Human monoclonal antibody VP5G3 (IgM) from Arend Mulder (Leiden):							
	Sensitization due to pregnancy. Antibody producer types as HLA-A24, A32; B18, B60; Cw10, Cw7.						
	Immunizing haplotype: HLA-A26; B55 (Bw6); Cw1						
	Data supplied by Marilyn Marrari (Pittsburgh):						
	PANEL OLMFI GP MFI						
	Positive control nt nt						
	Negative control 9 5 163RE+ A*11:01 11150 8163						
	163RE+ A*11:01 11150 8163 163RE+ A*11:02 12567 4246						
	163RE+ A*25:01 13029 7194						
	Immunizing allele: 163RE+ A*26:01 12521 9514						
	163RE+ A*43:01 7510 1165						
	163RE+ A*66:01 12498 11044						
	Self Alleles 21 ± 11 9 ± 4						
	Other 163RE-negative alleles 84 ± 278 9 ± 3						
	Data from El-Awar et al, Human Immunology 68: 170-180, 2007: Serum eluate Z2076.@0						
	(absorbed with A*25:01 cells), no information on HLA types of antibody producer/immunizer						
	Epitope #209 Z2076.@0: Eluted from A2501 rHLA cell line						
	25 —						
	£ 20						
	Reaction strength 10 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2						
	on strengt						
	<u> 등</u> ^로 10						
	o a a						
	ž 5						
	A1102 A1102 A2501 A2601 B4201 A6602						
	A A A A A A A A A A A A A A A A A A A						
	aa position						
	Antigen 163 166 A0101 R D						
	A1101 R E						
	A1102 R E						
	A2501 P F						
	A2601 R E 163R → chain						
	A4301 R E						
	A6601 R E 166D						
	B4201 T E						
	A3401 T E						
	A6602 E E						
Other antibody assays:	Data from Mulder et al, Tissue Antigens 52: 393-396, 1998:						
	VP5G3 reacts with HLA-A11, A25, A26, A66 in CDC assays; A43 not tested.						
	Data from Fernandez-Vina et al, in <u>Immunobiology of the Human MHC vol. I</u> , John A. Hansen						
	(Ed), pp 890-931, 2006:						
	VP5G3 (13-WS 0061) positive with HLA-A*11:01, *11:02, *11:03, *24:10, *25:01, *25:02, *26:01,						
	*26:02, *26:03, *26:08, *26:15, *66:01 in CDC assays in 13 th IHWS. No HLA-A43 cells were tested.						
Comments:	Equivalent to TerEp #209. Epitope is not shared by HLA-A*66:02, but is shared by *24:10, which						
	was positive in CDC assays.						

Epitope-sharing Luminex alleles



All Alleles that Share Epitope



A Hom	Databas	
163EW	1620	3163E166
163GLS	1620	3163L166
163LW	1620	3163L166

Alleles of Epitope: 163RE Confirmed

A*02:101, A*02:135, A*02:154, A*02:38, A*11:01, A*11:02, A*11:03, A*11:05, A*11:06, A*11:07, A*11:08, A*11:09, A*11:10, A*11:11, A*11:12, A*11:13, A*11:14, A*11:15, A*11:16, A*11:17, A*11:18, A*11:19, A*11:20, A*11:22, A*11:23, A*11:24, A*11:25, A*11:26, A*11:29, A*11:30, A*11:31, A*11:32, A*11:33, A*11:34, A*11:36, A*11:37, A*11:40, A*11:41, A*11:42, A*24:10, A*25:01, A*25:02, A*25:03, A*25:04, A*25:05, A*25:07, A*25:08, A*26:01, A*26:02, A*26:03, A*26:05, A*26:06, A*26:07, A*26:08, A*26:10, A*26:12, A*26:13, A*26:14, A*26:15, A*26:16, A*26:17, A*26:18, A*26:19, A*26:20, A*26:21, A*26:22, A*26:23, A*26:24, A*26:26, A*26:27, A*26:28, A*26:30, A*26:31, A*26:32, A*26:33, A*26:35, A*26:36, A*26:37, A*26:38, A*31:24, A*36:04, A*43:01, A*66:01, A*66:04, A*66:05, A*66:06, A*66:07, A*66:08, A*66:09

Select a Database to View - DRB

Databases

ABC

DRB

DQB + DQA

DPB + DPA

MICA

Filters

Epitope	Polymorphic Residues	Frequency	Antibody Reactivity	Struct Epitope	Luminex Alleles	All Alleles
4Q	4Q		Provisional		DRB1*07:01, DRB1*09:01, DRB4*01:01, D More	DRB1*07:01, DRB1*07:09, DRB1*09:01, More
4R	4R				DRB1*01:01, DRB1*01:02, DRB1*01:03, D More	DRB1*01:01, DRB1*01:02, DRB1*01:03, More
6C2	6C(157I)				DRB5*02:02 More	DRB1*13:112, DRB1*13:128, DRB5*02:02, More
6R2	6R(157T)				DRB1*01:01, DRB1*01:02, DRB1*01:03, D More	DRB1*01:01, DRB1*01:02, DRB1*01:03, More
12TSE	12T13S14E		Confirmed		DRB1*03:01, DRB1*03:02, DRB1*03:03, D Moré	DRB1*03:01, DRB1*03:02, DRB1*03:03, More
13FE	13F14E		Provisional		DRB1*01:01, DRB1*01:02, DRB1*01:03, D Moré	DRB1*01:01, DRB1*01:02, DRB1*01:03, More
13FEL	13F14E26L		Provisional		DRB1*01:01, DRB1*01:02, DRB1*01:03, More	DRB1*01:01, DRB1*01:02, DRB1*01:03, More


Epitope Database Search Options

- Identify the epitope repertoire of any selected allele (Luminex or non-Luminex)
 - Choose antibody-verified or all epitopes
- 2. Identify all mismatched epitopes for a given HLA phenotype
 - Choose antibody-verified or all epitopes

These options can be combined to identify a donor allele's repertoire of epitopes that are mismatched for a recipient's HLA type

Identifying epitopes on non-Luminex alleles mismatched for a patient


Enter the non-Luminex allele of interest (e.g., donor) in the "Search by allele" field and the patient HLA type in the "HLA type of recipient" field; results show one epitope on non-Luminex A*03:02 that is not shared by the common A*03:01 found in the Luminex panels.



If screening results show antibody reactivity towards epitope 156Q, A*03:02 is likely an unacceptable allele!

Combining Options

Use Filters 2 and 3 in combination to display epitopes on an allele that are mismatched for a given HLA type, e.g., to identify epitope mismatches for a patient's HLA phenotype that are found on a specific donor allele.



Results of combined options

> Filters

Filters parameters: Antibody Reactivity is All and HLA Typing is A*11:01 and HLA Type of recipient is A*02:01, A*03:01, B*07:02, B*35:01, C*07:02

∢ Back

Epitope	Polymorphic Residues	Frequency	Antibody Reactivity	Struct Epitope	Luminex Alleles	All Alleles
151AHA	150A151H152A		Confirmed		A*11:01, A*11:02 More	A*01:26, A*02:27, A*11:01, A*11:02, A More
151HA	151H152A				A*01:01, A*11:01, A*11:02, A*36:01 More	A*01:01, A*01:02, A*01:03, A*01:06, A More
156Q	156Q				A*11:01, A*11:02, A*24:02, A*24:03, C More	A*01:12, A*01:19, A*01:25, A*02:12, A More
163R	163R		Provisional		A*01:01, A*11:01, A*11:02, A*25:01, A More	A*01:01, A*01:02, A*01:03, A*01:06, A More
163RE	162G163R166E167W		Confirmed	View	A*11:01, A*11:02, A*25:01, A*26:01, A More	A*02:101, A*02:135, A*02:154, A*02:38 More

We found 5 epitopes in the database.

The HLA Epitope Registry is a Work-In-Progress

- As of July 2013, 85 HLA-ABC, 54 DRB1/3/4/5,
 21 DQ (18 DQB1, 3 DQA1), 7 DPB1 and 24 MICA antibody-verified epitopes are listed
- Each database will be updated on a quarterly basis
- Currently working on a tool to allow users to print or create and download pdf files of results

New Antibody-Verified Epitopes

- An important aspect is the participation by HLA professionals who have identified antibodies specific for new and not-so-well described epitopes
- From the website one can download instructions for how to submit information about epitope-specific antibody reactivity

HLAMatchmaker Analysis of Sera from Sensitized Patients

Use of antibody-verified class I epitopes recorded in the International HLA Epitope Registry

Analysis of Epitope Specificity of HLA Antibody

HLA information about the sensitizing event

- High-resolution HLA typing of patient and the immunizing HLA antigen
- Provides information about patient's exposure to mismatched eplets
- Identification of immunizer eplets on alleles in the Luminex panel

Everybody Likes the Luminex Assay with Single Alleles

but

It's Not a Perfect Test!

Potential Limitations of Single Allele Luminex Assays

 Some Luminex kits have certain alleles with significant MFI values unrelated to allosensitization events (technical problems or do they reflect "natural" antibodies?)

Unexplained high MFI values with 129 first pregnancy sera with no antibodies against paternal HLA class I alleles (Study with Stefan Schaub, Basel, Switzerland)

	Nr of cases	Mean MFI + SD (Range)			
Self alleles	129	6 <u>+</u> 7 (1-55)			
Paternal alleles	299	9 <u>+</u> 17 (1-108)			
Luminex allele	Nr of cases	Adjusted MFI*	<u>Luminex allele</u>	Nr of cases	Adjusted MFI*
A*11:02	6	221,254,428,1033,1122,1493	B*14:02	1	835
B*15:12	5	201,209,314,391,709	B*40:02	1	365
A*29:01	4	237,251,519,3874	B*42:01	1	333
A*29:02	4	204,236,1864,3819	B*15:16	1	317
B*45:01	3	305,526,1718	B*67:01	1	310
A*68:02	3	304,889,1141	B*13:02	1	300
B*73:01	3	177,320,629	B*44:03	1	290
B*58:01	2	222,342	B*54:01	1	258
A*80:01	2	880,1726	B*18:01	1	225
B*57:01	2	203,229	B*44:02	1	225
B*82:01	2	272,578	A*26:01	1	224
C*17:01	1	2113	C*07:02	1	211
C*03:02	1	922	A*25:01	1	203

^{*}Adjusted MFI = observed MFI - (Mean MFI with self + 3 StDev) Only >200 values are shown

Antibody Verification of HLA Class I Epitopes

- Duquesnoy RJ, Marrari M, Mulder A, da M. Sousa LCD, Da Silva AS, do Monte SJH.
 'First Report on the Antibody Verification of HLA-ABC Epitopes Recorded in the HLA Epitope Registry'. *Tissue Antigens* 83:391-400, 2014
 - 97 HLA-ABC antibody-verified epitopes have been recorded, 62 correspond to eplets and
 35 are defined by eplets paired with other residue configurations

Serum Analysis with HLAMatchmaker

Three types of epitopes in the International Registry:

- 1. Antibody-verified epitopes defined by eplets*
- 2. Antibody-verified epitopes defined by eplet pairs*
- 3. Theoretical epitopes with distinct residue structures (might become antibody-verified?)

97 HLA-ABC antibody-verified epitopes have been recorded, 62 correspond to eplets and 35 are defined by eplets paired with other residue configurations

^{*}Duquesnoy RJ, Marrari M, Mulder A, da M. Sousa LCD, Da Silva AS, do Monte SJH. 'First Report on the Antibody Verification of HLA-ABC Epitopes Recorded in the HLA Epitope Registry'. *Tissue Antigens* 83:391-400, 2014

HLAMatchmaker Analysis for Antibody-Verified Epitopes

- Class I SAB data on 28 first pregnancy sera provided by Stefan Schaub (Basel, Switzerland)
- High-resolution types of mother and paternal haplotype of child
- Analysis only done for sera whereby at least one immunizing allele had MFI>2500

190000000000000000000000000000000000000										Numb	er of Reactive	Alleles	
		HLA Type	of	MFI	MFI	MFI	Mismate	ched Immuniz	er Alleles	HLA-A	HLA-B	HLA-C	
Case	Ant	ibody Pro	ducer	self	Cut-off	Pos Cont		MFI Values		MFI Range	MFI Range	MFI Range	CPRA
#186	Δ*11:01	A*24:02	R*07:02				A*03:02	B*27:05	C*01:02	1	7	2	32%
#186	B*39:06	C*07:02		7±5	100	7002	nd (01=286)	8953	7245	286	104-8953	691-7245	32,0
#254	A*01:01	A*03:01			-		A*31:01	B*27:05	C*01:02	0	2	8	56%
1254	B*57:01	C*02:02	C*06:02	4±3	100	8855	2	11	3025		2182-3061	210-3202	3070
1247	A*03:01	A*03:01	B*15:01		100	0033	A*02:01	Match	C*03:03	13	3	0	71%
#247	B*35:01	C*04:01	C*07:02	15±29	200	9736	4347	Maten	1	314-5951	724-1042		, 1,0
#233	A*02:01		B*15:18	13223	200	3730	Match	B*40:02	C*02:02	2	31	1	71%
1233	B*51:01		C*15:02	86±39	200	8285	Widter	9647	430	7976	226-11608	430	11/0
1373	A*02:01	A*11:01	B*35:03	00133	200	0203	A*29:01	B*08:01	C*07:02	25	32	3	73%
1373	B*35:01		C*04:01	1±0	100	8695	8649	10629	5	559-10276	117-10629	112-144	1370
129	A*01:01	A*23:01		110	100	8093	A*30:02	B*13:02	C*06:02	28	27	7	75%
	B*49:01	C*07:01		3±3	100	9719	10888	8982	5712	118-11108	103-8982	256-7653	/5/0
129	A*32:01	A*32:01		313	100	9/19	A*11:01	B*51:01	C*15:02	1	13	9	76%
355	B*38:01	C*03:03	C*12:03	46±45	200	7861	47	8272	11977	583	243-8272	1075-11977	7070
	A*01:01		B*35:03	40145	200	7801				8		0	77%
354		A*02:01		015	***	0050	A*30:01	B*51:01	C*14:03	E-1510 - 1510 -	20	U	11%
354	B*40:01	C*01:02		8±6	100	8353	5769	5500	nd (02=3)	2609-7792	102-7297	2	700/
100	A*11:01	A*11:01					A*24:02	B*55:01	C*03:03	2	27	2	78%
100	B*40:02	C*02:02	C*04:01	5±4	100	8341	8	11270	14	132-169	102-11270	186-471	
387	A*03:01	A*03:01	B*07:02	75572	2000	17030502	A*02:05	B*51:01	C*16:02	15	33	3	87%
1387	B*57:02		C*18:01	3±3	100	8180	nd (01=8498)	10242	nd (01=1)	155-8988	132-10242	218-568	
1334	A*01:01	A*03:01	B*08:01				A*23:01	B*27:02	C*02:02	7	28	0	88%
1334	B*35:03	C*07:01	C*07:02	4±7	100	9685	8407	nd (05=5821)	9	105-8978	121-8693		
188	A*01:01	A*03:01	B*08:01				A*02:01	B*51:01	C*15:02	12	31	1	90%
188	B*37:01	C*06:02	C*07:01	8±9	100	11215	9506	10487	47	165-11355	282-10994	135	
369	A*26:01	A*30:01	B*18:01				A*02:01	B*15:01	C*03:04	9	32	3	90%
1369	B*38:01	C*07:01	C*12:03	4±2	100	9197	2879	12245	2848	172-3194	107-12245	2848-4268	
185	A*02:01	A*30:01	B*13:02				A*68:01	B*35:01	C*07:02	0	11	11	91%
185	B*14:02	C*06:02	C*08:02	8±3	100	9641	18	270	3383		134-293	163-12308	
177	A*01:01	A*02:01	B*40:02				A*03:01	B*07:02	C*07:02	0	11	10	92%
177	B*57:01	C*02:02	C*06:02	30±41	200	9001	8	3379	3045		469-13249	606-11695	
87	A*01:01	A*68:01	B*40:01				A*02:01	B*35:01	C*04:01	3	28	7	93%
187	B*44:02	C*03:04	C*07:04	2±2	100	11120	358	6814	183	216-358	130-6951	162-2563	
1376	A*31:01	A*32:01	B*27:05				A*02:01	B*51:01	C*15:02	13	25	0	94%
1376	B*40:01	C*01:02	C*03:04	7±5	100	8580	2947	2034	42	159-3949	218-2441		
189	A*24:02	A*32:01	B*35:03				A*01:01	B*08:01	C*07:01	27	3	7	95%
189	B*44:29	C*05:01	C*12:03	1±1	100	8614	11998	1800	nd (02=7107	241-13734	486-14956	256-10851	
316	A*02:01	A*03:01	B*07:02				A*24:02	B*40:01	C*03:04	7	39	11	95%
316	B*18:01	C*07:01	C*07:02	67±91	400	8538	8916	11888	9587	3434-11850	441-12522	539-10443	
228	A*01:01	A*24:02	B*08:01				A*02:01	B*15:01	C*03:04	28	42	7	96%
228	B*40:02	C*02:02	C*07:01	117±131	500	7311	10395	9061	6174	814-12334	629-13490	1120-8945	
159	A*01:01	A*68:01	B*44:02				A*02:01	6421	C*06:02	4	33	4	96%
159	B*51:01	C*14:02	C*14:03	3+3	100	8709	5136	6421	489	165-6456	108-6421	264-497	
353	A*30:02	A*30:02	B*18:01				A*02:01	B*49:01	C*07:01	12	43	1	97%
353	B*18:01	C*05:01	C*05:01	80±133	500	7792	3720	9367	nd (02=1)	542-9855	553-13957	824	20.70
70	A*11:01	A*68:01	B*07:02	002133	300	1132	A*02:05	B*50:01	C*06:02	0	46	4	98%
70	B*07:02		C*07:02	15±24	100	9299	nd (01=1)	7891	124		135-7891	124-288	3070
49	A*02:01	A*02:01	B*15:01	19124	100	9299	A*01:01	B*58:01	C*07:01	25	15	4	98%
49	B*51:01	C*01:02	C*03:03	33±78	300	10440	11818	6305	nd (02=1418	5698-13117	455-13108	857-6987	3070
24	A*24:02	A*32:01	B*07:02	33T18	300	10440	A*02:01	B*44:02	C*05:01	26	455-13108	1	99%
	B*41:02			640	100	9637						376	39%
24		C*07:02	C*17:03	6±9	100	8627	7609	6742	376	529-7928	108-12019		4000
275	A*02:01		B*44:05		***	0577	A*03:02	B*18:01	C*07:01	27	41	8	1009
275	B*57:01	C*02:02	C*06:02	2±2	100	8573	nd (01=8487)	7916	nd (02=39)	157-6798	130-7916	489-2139	- 200-
384	A*03:01	A*33:01	B*14:02				A*24:02	B*40:06	C*15:02	15	38	12	1009
384	B*15:18	C*07:04	C*08:02	11±7	100	8644	6122	8106	8227	206-8802	107-11983	114-8426	
1392	A*11:01	A*32:01	B*35:03				A*02:01	B*49:01	C*07:01	10	46	15	100%
#392	B*35:01	C*04:01	C*04:01	270±96	600	9291	11153	7810	d (02=1257)	5963-12732	772-12611	2295-12908	

Epitope Analysis Approach

- Determine antibody specificities to antibodyverified epitopes recorded in the Registry What proportion reactive alleles carry such epitopes?
- 2. Analyze the remaining antibody reactivity and look for informative alleles expressing eplet-defined epitopes
- 3. Such epitopes might be classified as being newly antibody-verified

	Immunizing Allele Antibody-Verified	N	umbers o	f Antibo	dy-Verifie	d
	Epitopes on Reactive Alleles	Epi	tope-Car	rying Re	active Alle	eles
Case	The same of the same and the sa	HLA-A	HLA-B	HLA-C	Total	
#186	71ATD,161D	1/1	1/7	0/2	2/10	20%
#254	73TVS,76VS+152RE	0/0	1/2	8/8	9/10	90%
#247	127K, 62GE	9/13	3/3	0/0	12/16	75%
#233	41T, 163EW	1/2	17/31	0/1	18/34	53%
#373	62LQ,66IF+163TEW,76ANT,180E	7/25	8/32	0/3	15/60	25%
#129	56R,80K,144QL	3/28	2/27	7/7	12/62	19%
#355	44RT+69TNT,80K	0/1	8/13	7/9	15/23	65%
#354	56R, 80I,82LR	8/8	19/20	0/0	27/28	96%
#100	65QIA,69AA,163TEW+65QI	0/2	24/27	0/2	24/31	77%
#387	44RT+69TNT,127K,144TKH,163LW+65QI	9/15	18/33	0/3	27/51	53%
#334	65GK,80I,82LR,163EW+73TE	5/7	26/28	0/0	31/35	89%
#188	80I,131S+163LW,144TKH	11/12	22/31	0/1	33/44	75%
#369	44RMA,127K,144TKH,163LW,173K	9/9	23/32	3/3	35/44	80%
#85	44RT,62GE,80K,163TW+65QI,267QE	0/0	1/11	2/11	3/22	14%
#177	65QIA+76ESN,76VRN,267QE	0/0	11/11	10/10	21/21	100%
#87	62GE,44RT,80K,131S+163LW	3/3	22/28	7/7	32/38	84%
#376	131S+163LW,150AAH	11/13	20/25	0/0	31/38	82%
#189	90D,76ANT,138MI+79GT,267QE	21/27	1/3	5/7	27/37	73%
#316	41T,73TVS,82LR,166DG,219W	7/7	27/39	9/11	43/57	75%
#228	44RMA,76VS+152RE,144TKH,144K+76VDT,163LW,173K	9/28	24/42	6/7	39/77	51%
#159	62GE,76ESN,107W	4/4	31/33	0/4	35/41	85%
#353	82LR, 41T,131S+163LW,144TKH	11/12	34/43	0/1	45/56	80%
#70	41T, 69TNT, 131S+163LW	0/0	40/46	0/4	40/50	80%
#49	65RNA+80I,138MI+79GT,144KR,166DG check c ep	25/25	5/15	4/4	34/44	77%
#24	62GE,142TKH,80T,166ES	26/26	12/22	1/1	39/49	80%
#275	73TS, 76ESN, 44RT+69TNT,138MI,144KR,163TEW+65QI	22/27	37/41	7/8	66/76	87%
#384	21H,41T,80K, 82LR,127K,163EW,167DG	14/15	31/38	10/12	55/65	85%
#392	1C,41T,62GE,76VRN,82LR+138T,127K,267QE	10/10	27/46	15/15	52/71	73%

Which additional epitopes might be recognized by antibodies in these first pregnancy sera?

For what proportions of reactive alleles can we identify specific epitopes?

	Additional Epitopes	Total Number of		Numbers of Remaining
	on Reactive Alleles	Epitope-Carrying Rea	ctive Alleles	Reactive Alleles (MFI)*
Case		CONTRACTOR SERVICE AND ADDRESS OF THE SERVICE AN		5-949-9-07-08-07-92-07-00. \$10-84-07-07-#
#186	6K,71KA, 76ED	7/10	70%	3 (104-108; C*14:02=691)
#254	None	9/10	90%	1 (B*73:01=3061)
#247	None	12/16	75%	4(314-384; A*29:01=650; A*29:02=620)
#233	80N+66I	33/34	97%	1 (430)
#373	62RN+163TW,71STN,245AS	42/60	70%	18 (117-365;A*03:01;B*37:01=690;B*40:02=831;A*30:01=4947)
#129	66NV, 80N+45E (TP?)163TEW+182T	61/62	98%	1 (297)
#355	21H94I+91G	18/23	78%	5(243-467;A*33:01=583;B*14:02=1062;B*15:02=1859)
#354	None	27/28	96%	1 (101)
#100	None	24/31	77%	7 (102-186;C*03:02=471)
#387	69TNT+41A,131S+163LW+62R	41/51	80%	10(132-400; A*33:01=1658; B*54:01=2440)
#334	71KA	32/35	91%	3(105-121)
#188	170RH	38/44	70%	6 (186-345; B*39:01=447, B*67:01=493; B*15:12=510)
#369	None	35/44	80%	9 (107-353; B*40:06=602)
#85	80N+138T,163LW+65QI+70N74Y171Y	22/22	100%	0
#177	None	21/21	100%	0
#87	1315	34/38	89%	4(130-420; B*54:01=750; B*15:12=1732)
#376	144AH+161E	33/38	87%	5 (121-343)
#189	142TKH (TP?)	33/37	86%	4(156-256; B*15:12=486;C*15:02=606)
#316	63EI	49/57	86%	8(441-646;B*15:11=916;B*82:01=1111;B*15:02=1368;B*15:10=1708)
#228	131S, 166EW+182T	69/77	89%	8 (297-758;A*80:01=4483)
#159	80K+14R+16G+138T?	39/41	95%	2(333; 849:01=5167)
#353	131S+170RY	51/56	91%	5(542-718;B*07:02=1310;B*42:01=1639)
#70	1315	46/50	92%	4 (124-288)
#49	138MI,69AA+180Q,166ES (TP)	43/44	98%	1 (B*15:13=867)
#24	None	55/65	85%	10 (108-263; B*15:12=8306)
#275	66NV,69TNT+41A	76/76	100%	0
#384	None	55/65	85%	10 (106-308;B*42:01=404;B*08:01=458;B*82:01=512)
#392	14R,193PI+183D	70/71	99%	1 (772)

*List only alleles with MFI values more than 300 above cut-off values


Conclusion

The HLAMatchmaker version with antibody-verified class I epitopes works quite well but more antibody-verified epitopes need to be added

Principles of HLAMatchmaker-based antibody analysis programs

Two examples: HLA-DP HLA-C

Luminex Example of Anti-DP Reactivity (Patient Type: DPB1*0201,-



Anti- HLA-DP Reactivity of Serum Group B Pt 43, Patient types as DPB1*0201,-

CON3	X	X	76	
CON1	X	X	107	
CON ₂	X	X	121	
P 77	X	X	7274	
P 112	DPB1*0101	DPA1*0103	2596	
P 113	DPB1*0101	DPA1*0201	5228	
P 114	DPB1*0101	DPA1*0202	5932	
P 115	DPB1*0101	DPA1*0301	2603	
P 116	DPB1*0201	DPA1*0103	425	SELF
P 117	DPB1*0301	DPA1*0103	2957	
P 118	DPB1*0401	DPA1*0103	894	
P 119	DPB1*0401	DPA1*0201	3807	
P 120	DPB1*0401	DPA1*0202	3650	
P 121	DPB1*0401	DPA1*0301	741	
P 122	DPB1*0402	DPA1*0103	727	
P 123	DPB1*0402	DPA1*0301	832	
P 124	DPB1*0501	DPA1*0103	2958	
P 125	DPB1*0501	DPA1*0201	5863	
P 126	DPB1*0501	DPA1*0202	4790	
P 127	DPB1*0501	DPA1*0301	2714	
P 128	DPB1*1301	DPA1*0201	5080	
P 129	DPB1*1401	DPA1*0201	5812	
P 130	DPB1*1701	DPA1*0201	5104	
P 131	DPB1*1801	DPA1*0103	423	
P 132	DPB1*1901	DPA1*0201	4878	
P 133	DPB1*1901	DPA1*0301	2233	
P 134	DPB1*2801	DPA1*0202	3814	

Anti- HLA-DP Reactivity of Serum Group B Pt 43 Patient types as DPB1*0201,-

	,		,	
CON3	X	X	76	
CON1	X	X	107	
CON2	X	X	121	
P 77	X	X	7274	
P 112	DPB1*0101	DPA1*0103	2596	
P 113	DPB1*0101	DPA1*0201	5228	
P 114	DPB1*0101	DPA1*0202	5932	
P 115	DPB1*0101	DPA1*0301	2603	
P 116	DPB1*0201	DPA1*0103	425	SELF
P 117	DPB1*0301	DPA1*0103	2957	
P 118	DPB1*0401	DPA1*0103	894	
P 119	DPB1*0401	DPA1*0201	3807	
P 120	DPB1*0401	DPA1*0202	3650	
P 121	DPB1*0401	DPA1*0301	741	
P 122	DPB1*0402	DPA1*0103	727	
P 123	DPB1*0402	DPA1*0301	832	
P 124	DPB1*0501	DPA1*0103	2958	Questions:
P 125	DPB1*0501	DPA1*0201	5863	
P 126	DPB1*0501	DPA1*0202	4790	Do the antibodies react with DPB or DPA or both?
P 127	DPB1*0501	DPA1*0301	2714	What epitopes are recognized?
P 128	DPB1*1301	DPA1*0201	5080	Which DP antigens are acceptable mismatches?
P 129	DPB1*1401	DPA1*0201	5812	Which DP antigens are unacceptable?
P 130	DPB1*1701	DPA1*0201	5104	
P 131	DPB1*1801	DPA1*0103	423	
P 132	DPB1*1901	DPA1*0201	4878	
P 133	DPB1*1901	DPA1*0301	2233	

HLAMatchmaker Analysis of Anti- HLA-DP Reactivity of Serum Group B Pt 43

Step 1: Show all eplets in the panel that are mismatched for this patient (Note the eplets on DPA1*0103 only the "SELF" DPB1*0201)

_	ONIO			70				
	ON3		X	76				
	ON1		X	107				
	· · · -	X	X	121				224
Р	77	X	X	7274		mmEp	DPB Eplets	DPA Eplets
Р	112	DPB1*0101	DPA1*0103	2596		15	8V,,,,35YA,,56AE,,65DIK,69IKR,70GKR,76V,84DE,87AV,,,,,,	18P,28E,51QA,83T,111K,127L,,
Р	113	DPB1*0101	DPA1*0201	5228		15	8V,,,,35YA,,56AE,,65DIK,69IKR,70GKR,76V,84DE,87AV,,,,,,	18P,28E,51RA,83A,111R,127P,,
Р	114	DPB1*0101	DPA1*0202	5932		15	8V,,,,35YA,,56AE,,65DIK,69IKR,70GKR,76V,84DE,87AV,,,,,,	18P,28E,51RA,83A,111R,127P,,
Р	115	DPB1*0101	DPA1*0301	2603		15	8V,,,,35YA,,56AE,,65DIK,69IKR,70GKR,76V,84DE,87AV,,,,,,	18P,28E,51QA,83T,111K,127L,,
Р	116	DPB1*0201	DPA1*0103	425	SELF	6		18P,28E,51QA,83T,111K,127L,,
Р	117	DPB1*0301	DPA1*0103	2957		15	8V,11L,,,,56ED,64DL,65DLK,,70GKR,76V,84DE,87AV,,,,,,,,	18P,28E,51QA,83T,111K,127L,,
Р	118	DPB1*0401	DPA1*0103	894		11	,,,,35FA,,56AE,,65DIK,69IKR,70GKR,,,,,,,	18P,28E,51QA,83T,111K,127L,,
Р	119	DPB1*0401	DPA1*0201	3807		11	,,,,35FA,,56AE,,65DIK,69IKR,70GKR,,,,,,,	18P,28E,51RA,83A,111R,127P,,
Р	120	DPB1*0401	DPA1*0202	3650		11	,,,,35FA,,56AE,,65DIK,69IKR,70GKR,,,,,,,	18P,28E,51RA,83A,111R,127P,,
Р	121	DPB1*0401	DPA1*0301	741		11	,,,,35FA,,56AE,,65DIK,69IKR,70GKR,,,,,,,	18P,28E,51QA,83T,111K,127L,,
Р	122	DPB1*0402	DPA1*0103	727		9	,,,,,,65DIK,69IKR,70GKR,,,,,,,	18P,28E,51QA,83T,111K,127L,,
Р	123	DPB1*0402	DPA1*0301	832		9	,,,,,,65DIK,69IKR,70GKR,,,,,,,	18P,28E,51QA,83T,111K,127L,,
Р	124	DPB1*0501	DPA1*0103	2958		13	,,,,35LV,,56AE,,65DIK,69IKR,70GKR,,84DE,87AV,,,,,,	18P,28E,51QA,83T,111K,127L,,
Р	125	DPB1*0501	DPA1*0201	5863		13	,,,,35LV,,56AE,,65DIK,69IKR,70GKR,,84DE,87AV,,,,,,	18P,28E,51RA,83A,111R,127P,,
Р	126	DPB1*0501	DPA1*0202	4790		13	,,,,35LV,,56AE,,65DIK,69IKR,70GKR,,84DE,87AV,,,,,,	18P,28E,51RA,83A,111R,127P,,
Р	127	DPB1*0501	DPA1*0301	2714		13	,,,,35LV,,56AE,,65DIK,69IKR,70GKR,,84DE,87AV,,,,,,,	18P,28E,51QA,83T,111K,127L,,
Р	128	DPB1*1301	DPA1*0201	5080		13	8V,11L,,,35YA,,56AE,,,,,76I,84DE,87AV,,,,,,,	18P,28E,51RA,83A,111R,127P,,
Р	129	DPB1*1401	DPA1*0201	5812		15	8V,11L,,,,56ED,64DL,65DLK,,70GKR,76V,84DE,87AV,,,,,,,,	18P,28E,51RA,83A,111R,127P,,
Р	130	DPB1*1701	DPA1*0201	5104		11	8V,11L,,,,56ED,,,,,84DE,87AV,,,,,,,	18P,28E,51RA,83A,111R,127P,,
Р	131	DPB1*1801	DPA1*0103	423		11	8V,,,,,,65DIK,69IKR,70GKR,,84VG,,,,,,	18P,28E,51QA,83T,111K,127L,,
Р	132	DPB1*1901	DPA1*0201	4878		10	,,,,,56AE,,,,76I,84DE,87AV,,,,,,	18P,28E,51RA,83A,111R,127P,,
Р	133	DPB1*1901	DPA1*0301	2233		10	,,,,,56AE,,,,,76I,84DE,87AV,,,,,,	18P,28E,51QA,83T,111K,127L,,
Р	134	DPB1*2801	DPA1*0202	3814		11	,,,,35FA,,,64DL,65DLK,,70GKR,,84VG,,,,,,,	18P,28E,51RA,83A,111R,127P,,

HLAMatchmaker Analysis of Anti- HLA-DP Reactivity of Serum Group B Pt 43

Step 2: After recording DPA1*0103 as negative in the program, identify other negative alleles and enter them in the program

CON3	X	X	76				
CON1	X	X	107				
CON2	X	X	121				
P 77	X	X	7274		mmEp	DPB Eplets	DPA Eplets
P 112	DPB1*0101	DPA1*0103	2596		9	8V,,,,35YA,,56AE,,65DIK,69IKR,70GKR,76V,84DE,87AV,,,,,,	1111111
P 113	DPB1*0101	DPA1*0201	5228		13	8V,,,,35YA,,56AE,,65DIK,69IKR,70GKR,76V,84DE,87AV,,,,,,	,,51RA,83A,111R,127P,,
P 114	DPB1*0101	DPA1*0202	5932		13	8V,,,,35YA,,56AE,,65DIK,69IKR,70GKR,76V,84DE,87AV,,,,,,	,,51RA,83A,111R,127P,,
P 115	DPB1*0101	DPA1*0301	2603		9	8V,,,,35YA,,56AE,,65DIK,69IKR,70GKR,76V,84DE,87AV,,,,,,	
P 116	DPB1*0201	DPA1*0103	425	SELF	0		,,,,,,
P 117	DPB1*0301	DPA1*0103	2957		9	8V,11L,,,,56ED,64DL,65DLK,,70GKR,76V,84DE,87AV,,,,,,,,	,,,,,,
P 118	DPB1*0401	DPA1*0103	894		5	,,,,35FA,,56AE,,65DIK,69IKR,70GKR,,,,,,,	,,,,,,
P 119	DPB1*0401	DPA1*0201	3807		9	,,,,35FA,,56AE,,65DIK,69IKR,70GKR,,,,,,,	,,51RA,83A,111R,127P,,
P 120	DPB1*0401	DPA1*0202	3650		9		,,51RA,83A,111R,127P,,
P 121	DPB1*0401	DPA1*0301	741	NEG	5	,,,,35FA,,56AE,,65DIK,69IKR,70GKR,,,,,,,	1111111
P 122	DPB1*0402	DPA1*0103	727	NEG	3	,,,,,,65DIK,69IKR,70GKR,,,,,,,	1111111
P 123	DPB1*0402	DPA1*0301	832	NEG	3	,,,,,,65DIK,69IKR,70GKR,,,,,,,	1111111
P 124	DPB1*0501	DPA1*0103	2958		7	,,,,35LV,,56AE,,65DIK,69IKR,70GKR,,84DE,87AV,,,,,,,,	1111111
P 125	DPB1*0501	DPA1*0201	5863		11	,,,,35LV,,56AE,,65DIK,69IKR,70GKR,,84DE,87AV,,,,,,,	,,51RA,83A,111R,127P,,
P 126	DPB1*0501	DPA1*0202	4790		11	,,,,35LV,,56AE,,65DIK,69IKR,70GKR,,84DE,87AV,,,,,,,	,,51RA,83A,111R,127P,,
P 127	DPB1*0501	DPA1*0301	2714		7	,,,,35LV,,56AE,,65DIK,69IKR,70GKR,,84DE,87AV,,,,,,,	,,,,,,,
P 128	DPB1*1301	DPA1*0201	5080		11	8V,11L,,,35YA,,56AE,,,,,76I,84DE,87AV,,,,,,,	,,51RA,83A,111R,127P,,
P 129	DPB1*1401	DPA1*0201	5812		13	8V,11L,,,,,56ED,64DL,65DLK,,70GKR,76V,84DE,87AV,,,,,,,,	,,51RA,83A,111R,127P,,
P 130	DPB1*1701	DPA1*0201	5104		9	8V,11L,,,,56ED,,,,,84DE,87AV,,,,,,	,,51RA,83A,111R,127P,,
P 131	DPB1*1801	DPA1*0103	423	NEG	5	8V,,,,,,65DIK,69IKR,70GKR,,84VG,,,,,,	*******
P 132	DPB1*1901	DPA1*0201	4878		8	,,,,,56AE,,,,,76I,84DE,87AV,,,,,,	,,51RA,83A,111R,127P,,
P 133	DPB1*1901	DPA1*0301	2233		4	,,,,,56AE,,,,,76I,84DE,87AV,,,,,,	*******
P 134	DPB1*2801	DPA1*0202	3814		9	,,,,35FA,,,64DL,65DLK,,70GKR,,84VG,,,,,,,	,,51RA,83A,111R,127P,,

HLAMatchmaker Analysis of Anti- HLA-DP Reactivity of Serum Group B Pt 43

Step 3: Remaining eplets after entering the negative DP alleles in the program

CON3	X	X	76				
CON1	X	X	107				
CON2	X	X	121				
P 77	X	X	7274		mmEp	DPB Eplets	DPA Eplets
P 112	DPB1*0101	DPA1*0103	2596		4	,,,,35YA,,,,,,76V,84DE,87AV,,,,,,,	,,,,,,
P 113	DPB1*0101	DPA1*0201	5228		8	,,,,35YA,,,,,,76V,84DE,87AV,,,,,,,	,,51RA,83A,111R,127P,,
P 114	DPB1*0101	DPA1*0202	5932		8	,,,,35YA,,,,,,76V,84DE,87AV,,,,,,	,,51RA,83A,111R,127P,,
P 115	DPB1*0101	DPA1*0301	2603		4	,,,,35YA,,,,,,76V,84DE,87AV,,,,,,,	,,,,,,
P 116	DPB1*0201	DPA1*0103	425	SELF	0		,,,,,,
P 117	DPB1*0301	DPA1*0103	2957		7	,11L,,,,,56ED,64DL,65DLK,,,76V,84DE,87AV,,,,,,,,	,,,,,,
P 118	DPB1*0401	DPA1*0103	894		0		,,,,,,
P 119	DPB1*0401	DPA1*0201	3807		4		,,51RA,83A,111R,127P,,
P 120	DPB1*0401	DPA1*0202	3650		4		,,51RA,83A,111R,127P,,
P 121	DPB1*0401	DPA1*0301	741	NEG	0		,,,,,,,
P 122	DPB1*0402	DPA1*0103	727	NEG	0		,,,,,,,
P 123	DPB1*0402	DPA1*0301	832	NEG	0		,,,,,,,
P 124	DPB1*0501	DPA1*0103	2958		3	,,,,35LV,,,,,,,84DE,87AV,,,,,,,,	,,,,,,,
P 125	DPB1*0501	DPA1*0201	5863		7	,,,,35LV,,,,,,,84DE,87AV,,,,,,,	,,51RA,83A,111R,127P,,
P 126	DPB1*0501	DPA1*0202	4790		7	,,,,35LV,,,,,,,84DE,87AV,,,,,,,	,,51RA,83A,111R,127P,,
P 127	DPB1*0501	DPA1*0301	2714		3	,,,,35LV,,,,,,,84DE,87AV,,,,,,,	,,,,,,,
P 128	DPB1*1301	DPA1*0201	5080		9	,11L,,,35YA,,,,,,76I,84DE,87AV,,,,,,,	,,51RA,83A,111R,127P,,
P 129	DPB1*1401	DPA1*0201	5812		11	,11L,,,,,56ED,64DL,65DLK,,,76V,84DE,87AV,,,,,,,	,,51RA,83A,111R,127P,,
P 130	DPB1*1701	DPA1*0201	5104		8	,11L,,,,,56ED,,,,,,84DE,87AV,,,,,,,	,,51RA,83A,111R,127P,,
P 131	DPB1*1801	DPA1*0103	423	NEG	0		,,,,,,,
P 132	DPB1*1901	DPA1*0201	4878		7	,,,,,,,,,76I,84DE,87AV,,,,,,,	,,51RA,83A,111R,127P,,
P 133	DPB1*1901	DPA1*0301	2233		3	,,,,,,,,,76I,84DE,87AV,,,,,,,,	,,,,,,
P 134	DPB1*2801	DPA1*0202	3814		6	,,,,,,64DL,65DLK,,,,,,,,,,	,,51RA,83A,111R,127P,,

HLAMatchmaker Analysis of Anti- HLA-DP Reactivity of Serum Group B Pt 43

Step 4: determine what eplets are shared between reactive alleles

CON3	X	X	76				
CON1	X	X	107				
CON2	X	X	121				
P 77	X	X	7274		mmEp	DPB Eplets	DPA Eplets
P 112	DPB1*0101	DPA1*0103	2596		4	,,,,35YA,,,,,,76V,84DE,87AV,,,,,,	
P 113	DPB1*0101	DPA1*0201	5228		8	,,,,35YA,,,,,,76V,84DE,87AV,,,,,,	,, 51RA,83A ,111R,127P,,
P 114	DPB1*0101	DPA1*0202	5932		8	,,,,35YA,,,,,,76V,84DE,87AV,,,,,,	,, 51RA,83A ,111R,127P,,
P 115	DPB1*0101	DPA1*0301	2603		4	,,,,35YA,,,,,,76V,84DE,87AV,,,,,,	,,,,,,
P 116	DPB1*0201	DPA1*0103	425	SELF	0		,,,,,,
P 117	DPB1*0301	DPA1*0103	2957		7	,11L,,,,,56ED,64DL,65DLK,,,76V, 84DE,87AV ,,,,,,,,	,,,,,,
P 118	DPB1*0401	DPA1*0103	894		0		,,,,,,
P 119	DPB1*0401	DPA1*0201	3807		4		,, 51RA,83A ,111R,127P,,
P 120	DPB1*0401	DPA1*0202	3650		4		,, 51RA,83A ,111R,127P,,
P 121	DPB1*0401	DPA1*0301	741	NEG	0		,,,,,,,
P 122	DPB1*0402	DPA1*0103	727	NEG	0		,,,,,,,
P 123	DPB1*0402	DPA1*0301	832	NEG	0		,,,,,,,
P 124	DPB1*0501	DPA1*0103	2958		3	,,,,35LV,,,,,,,84DE,87AV,,,,,,,	,,,,,,,
P 125	DPB1*0501	DPA1*0201	5863		7	,,,,35LV,,,,,,,84DE,87AV,,,,,,,	,, 51RA,83A ,111R,127P,,
P 126	DPB1*0501	DPA1*0202	4790		7	,,,,35LV,,,,,,,84DE,87AV,,,,,,,,	,, 51RA,83A ,111R,127P,,
P 127	DPB1*0501	DPA1*0301	2714		3	,,,,35LV,,,,,,,84DE,87AV,,,,,,,	,,,,,,,
P 128	DPB1*1301	DPA1*0201	5080		9	,11L,,,35YA,,,,,,76I, 84DE,87AV ,,,,,,,	,, 51RA,83A ,111R,127P,,
P 129	DPB1*1401	DPA1*0201	5812		11	,11L,,,,,56ED,64DL,65DLK,,,76V, 84DE,87AV ,,,,,,,,	,, 51RA,83A ,111R,127P,,
P 130	DPB1*1701	DPA1*0201	5104		8	,11L,,,,,56ED,,,,,84DE,87AV,,,,,,,	,, 51RA,83A ,111R,127P,,
P 131	DPB1*1801	DPA1*0103	423	NEG	0		,,,,,,,
P 132	DPB1*1901	DPA1*0201	4878		7	,,,,,,,,,76l,84DE,87AV,,,,,,,,	,, 51RA,83A ,111R,127P,,
P 133	DPB1*1901	DPA1*0301	2233		3	,,,,,,,,,76l,84DE,87AV,,,,,,,,	,,,,,,
P 134	DPB1*2801	DPA1*0202	3814		6	,,,,,,64DL,65DLK,,,,,,,,,,	,, 51RA,83A ,111R,127P,,


HLAMatchmaker-Predicted Unacceptable DPB Alleles not Present in the Luminex Panel

DPB1*0601	8V,11L,,,,,56ED,64DL,65DLE,,,, 84DE,87AV ,,	DPB1*5601	8V,11L,,,,,64DL,65DLK,,,76V, 84DE,87AV ,,
DPB1*0801	,,,,,,,,76V,84DE,87AV,,	DPB1*5701	,,,,,56ED,64DL,65DLK,,,76V, 84DE ,,,
DPB1*1601	,,,,,,,,,84DE,87AV,,	DPB1*5801	8V,11L,,,35LV,,,,,,84DE,87AV,,
DPB1*2001	8V,11L,,,,56ED,64DL,65DLK,,, ,84DE,87AV ,,	DPB1*6301	,,,,35LV,,,,,,,84DE,87AV,,
DPB1*2101	8V,11L,,,35LV,,,,,,84DE,87AV,,	DPB1*6501	,,,,35YA,,,,,,76V,84DE,87AV,,
DPB1*2201	,,,,35LV,,,,,,,84DE,87AV,,	DPB1*6701	8V,11L,,,,,64DL,65DLK,,,76V, 84DE,87AV ,,
DPB1*2501	8V,11L,,,,,64DL,65DLK,,,76V, 84DE,87A V,,	DPB1*6801	,,,,,,,,76V,84DE,87AV,,
DPB1*2601	8V,11L,,,35YA,,,,,,76V, 84DE,87AV ,,	DPB1*6901	8V,11L,,,,56ED,64DL,65DLR,,,, 84DE,87AV ,,
DPB1*2701	8V,11L,,,35YA,,,,,, 84DE,87AV ,,	DPB1*7001	8V,11L,,,,56ED,64DL,65DLK,,,76V, 84DE,87AV ,,
DPB1*2901	8V,11L,,,,56ED,64DL,65DLE,,,76V, 84DE,87AV ,,	DPB1*7601	8V,11L,,,,56ED,64DL,65DLK,,,76V, 84DE,87AV ,,
DPB1*3001	8V,11L,,,,,,,84DE,87AV,,	DPB1*7801	8V,11L,,,,56ED,64DL,65DLK,,,76V, 84DE,87AV, ,
DPB1*3101	,,,,,,64DL,65DLK,,,, 84DE,87AV ,,	DPB1*7901	8V,11L,,,,,,,76V,84DE,87AV,,
DPB1*3501	8V,11L,,,,56ED,,,,76V, 84DE,87AV ,,	DPB1*8401	,,,,,,,,76V,84DE,87AV,,
DPB1*3601	8V,11L,,,35LV,,,,,,84DE,87AV,,	DPB1*8501	8V,11L,,,35YA,,,,,, 84DE,87AV ,91H,
DPB1*3701	8V,11L,,,,,,,76V, 84DE,87AV ,,	DPB1*8701	8V,11L,,,,,64DL,65DLK,,,, 84DE,87AV ,,
DPB1*3801	,,,,35LV,,,,,,,84DE,87AV,,	DPB1*8801	8V,11L,,,,56ED,,,,,76V, 84DE,87AV ,,
DPB1*4401	8V,11L,,,35LV,,56ED,64DL,65DLE,,,76V, 84DE,87AV ,,	DPB1*8901	8V,,,,35YA,,,,,,, 84DE,87AV ,,
DPB1*4501	8V,11L,,,,,64DL,65DLK,,,76V, 84DE,87AV ,,	DPB1*9001	8V,,,,,,,,,,76V, 84DE,87AV ,,
DPB1*5001	8V,,,,,56ED,64DL,65DLK,,,76V, 84DE,87AV ,,	DPB1*9101	8V,11L,,,,56ED,64DL,65DLK,,,, 84DE,87AV ,,
DPB1*5201	8V,11L,,,,,64DL,65DLK,,,76V, 84DE,87AV ,,	DPB1*9201	8V,11L,,,,,56ED,64DL,65DLK,,,76V, 84DE,87AV ,,
DPB1*5401	8V,11L,,,,,,,,76V,84DE,87AV,,	DPB1*9301	8V,11L,,,,,,,,84DE,87AV,,
DPB1*5501	8V,11L,,,,,,,,84DE,87AV,,	DPB1*9701	,,,, <mark>35LV,43WR,,,,,,84DE,87AV,,</mark>
		DPB1*9801	8V,11L,,,,,56ED,,,,,,84DE,87AV,,

HLAMatchmaker-Predicted Acceptable DPB Alleles not Present in the Luminex Panel

```
DPB1*0202 1 ,,,,35LV,,,,,,,,
                                                 DPB1*6001 1 .....64DN......
           6 8V.,.33Q,35YA,,,64DL,65DLR,,,,84VG,,,
                                                 DPB1*6201 2 ....35LV.......84VG...
DPB1*1501
DPB1*1801 2 8V......84VG...
                                                 DPB1*6601 2 8V.11L....
DPB1*2301 0 .....
                                                 DPB1*7101 0 .....
                                                 DPB1*7201 2 ......64DL,65DLK......
DPB1*2401
           0 .....
DPB1*2801 3 ......64DL,65DLK,,,,84VG,,,
                                                 DPB1*7301 3 ,,,,,64DL,65DLK,,,76V,,,,
                                                 DPB1*7401 7 8V,11L,,33Q,35YA,,,64DL,65DLR,,,,84VG,,,
DPB1*3201 1 .....56EV.......
                                                 DPB1*7501 1 ......76V....
DPB1*3301 0 .....
DPB1*3401 4 ...,35LV,,,64DL,65DLK,,,,84VG,,,
                                                 DPB1*7701 0 ,.....
                                                 DPB1*8001 1 ....,56ED,...,...
DPB1*3901 1 ....35YA,,,,,,
DPB1*4001 2 ....35YA......84VG...
                                                 DPB1*8101 0 .....
DPB1*4101 3 ....,64DF,65DFE,69FER,,,,,
                                                 DPB1*8201 1 ...,91H,
                                                 DPB1*8301 2 ......64DF,65DFK,......
DPB1*4601 1 ....,56ED,,,,,,,
DPB1*4701 0 .....
                                                 DPB1*8601 3 8V.11L....56ED.......
DPB1*4801 1 ....35LV,....
                                                 DPB1*9401 1 ,...,43GW,,,,,,
DPB1*4901 1 ...,35YA,,,,,,,,
                                                 DPB1*9501 3 ....35LV...64DL,65DLE......
DPB1*5101 0 ,,,,,,,
                                                 DPB1*9601 2 ....35YA...64HI.......
DPB1*5301 2 ....35YA.......84VG...
                                                 DPB1*9901 1 ..28D.....
```

Molecular Locations of Positions 84 and 87



84DE+87AV Corresponds to an Antibody-Defined Epitope

HLA-DP Epitope Typing Using Monoclonal Antibodies

William H. Marshall, Sheila Drover, Dianne Codner, Jane Gamberg, M. Douglas Copp, Hong-Wei Liu, Lang-Tuo Deng, and H. Banfield Younghusband

Human Immunology 59, 189-197 (1998)

TABLE 4 Proposed specificities of the monoclonal antibodies

NFLD.M66	IgG1	DPB1:84-87:DEAV
NFLD.M126	IgG1	DPB1:84-87:DEAV
NFLD.M120	IgG2a	DPB1:85-87:GPM
NFLD.M123	IgM	DPB1:84-87:GGPM

Frequency of Anti-84DE,87AV Reactive Antibodies

Our experience:

- 78/355 (22%) HLA class II-reactive patient sera have anti-HLA-DP antibodies
- 33/78 (42%) react with 84DE,87AV

Frequency of Anti-84DE,87AV Reactive Antibodies

Our experience:

- 78/355 (22%) HLA-reactive patient sera have anti-HLA-DP antibodies
- 33/78 (42%) react with 84DE,87AV

Danny Youngs (Seattle) ASHI Quarterly 2004 29/67 (43%) of patients with anti-DP antibodies react with DEAV at position 84-87

HLAMatchmaker Determination of Unacceptable DPA Alleles

	Eplet	Unacceptable Alleles
DPA	51RA	*0108*0201*0202*0203*0401
DPA	83A	*0105*0201*0202*0203*0401
DPA	111R	*0201*0202
DPA	127P	*0201*0202*0401

HLA-C Antibodies

Example of Luminex Screen for Antibodies Specific for HLA-C (1)

	HLA-C Type
Patient	Cw*0602
Patient	Cw*0702
Imm Donor	Cw*0102
Imm Donor	Cw*0701

Bead	Allele	MFI	RX
1	NegCont	880	
2	PosCont	12591	
83	Cw*0102	9850	IMM
84	Cw*0202	1054	
98	Cw*0302	2118	
97	Cw*0303	5498	
99	Cw*0304	4991	
85	Cw*0401	1393	
86	Cw*0501	1330	
87	Cw*0602	813	SELF
88	Cw*0702	624	SELF
89	Cw*0801	2465	
90	Cw*1203	767	
91	Cw*1402	7769	
92	Cw*1502	738	
93	Cw*1601	4305	
94	Cw*1701	798	
95	Cw*1802	1099	

What is the cut-off point to distinguish between positive and negative reactions?

Example of Luminex Screen for Antibodies Specific for HLA-C (2)

	HLA-C Type
Patient	Cw*0602
Patient	Cw*0702
Imm Donor	Cw*0102

Cw*0701

Imm Donor

Cut Off	1400	
Allele	MFI	RX
NegCont	880	
PosCont	12591	
Cw*0102	9850	IMM
Cw*0202	1054	NEG
Cw*0302	2118	POS
Cw*0303	5498	POS
Cw*0304	4991	POS
Cw*0401	1393	NEG
Cw*0501	1330	NEG
Cw*0602	813	SELF
Cw*0702	624	SELF
Cw*0801	2465	POS
Cw*1203	767	NEG
Cw*1402	7769	POS
Cw*1502	738	NEG
Cw*1601	4305	POS
Cw*1701	798	NEG
Cw*1802	1099	NEG
	Allele NegCont PosCont Cw*0102 Cw*0202 Cw*0302 Cw*0303 Cw*0304 Cw*0501 Cw*0602 Cw*0602 Cw*0702 Cw*0801 Cw*1203 Cw*1402 Cw*1502 Cw*1502 Cw*1601 Cw*1701	Allele MFI NegCont 880 PosCont 12591 Cw*0102 9850 Cw*0202 1054 Cw*0302 2118 Cw*0303 5498 Cw*0304 4991 Cw*0401 1393 Cw*0501 1330 Cw*0602 813 Cw*0602 813 Cw*0702 624 Cw*0801 2465 Cw*1203 767 Cw*1402 7769 Cw*1402 7769 Cw*1502 738 Cw*1601 4305 Cw*1701 798

Antibody react with Cw*0102 of donor Reactivity with donor's Cw*0701? No allele in panel What HLA-C epitopes are recognized?

Do HLAMatchmaker analysis What are the mismatched eplets?

Example of Luminex Screen for Antibodies Specific for HLA-C (3)

```
HLA-C Type
                Cw*0602
     Patient
     Patient
                Cw*0702
                Cw*0102 .1C,6K,.....69QRQT,....77TVS,..............219W,....
    Imm Donor
               Cw*0701 ,,,,,,65QNR,,,,,
    Imm Donor
       Cut Off
                1400
Bead Allele
                MFI
                         RX
                                Mismatched Eplets
     NegCont
                880
2
     PosCont
                12591
                                .....
                                ,1C,6K,.....69QRQT,....77TVS,......219W,....
83
     Cw*0102
                9850
                         IMM
                                .,21H,,,,,,69QRQT,,,,,77TVN,,,,,,,,,,,,,211T,,,,,
84
     Cw*0202
                1054
                         NEG
98
     Cw*0302
                2118
                                ,,21H,,,,,,69QRQT,,,,,77TVS,,,,,94II,,,,,,,163LW,173K,,,219W,,,,,
                         POS
                               ,,21H,,,,,,69QRQT,,,,,77TVS,,,,,94II,,,,,,,163LW,173K,,,219W,,,,,
97
     Cw*0303
                5498
                         POS
                         POS
                                ,,21H,,,,,,69QRQT,,,,,77TVS,,,,,94II,,,,,,,,163LW,173K,,,219W,,,,,
99
     Cw*0304
                4991
                         NEG
                                ,,17WR,,,,,,,,,,,113YN,116F,,,,,,219W,,,275KP,
85
     Cw*0401
                1393
                                ...35Q...46QGE....69QRQT.....77TVN.......113YN.116F.138K......177KT......275GP..
86
     Cw*0501
                1330
                         NEG
87
     Cw*0602
                813
                         SELF
                                .....
88
     Cw*0702
                624
                         SELF
                                ...35Q...46QGE....69QRQT.....77TVS.......113YN,116F....,152RT.,177KT......275GP..
89
     Cw*0801
                2465
                         POS
                         NEG
90
     Cw*1203
                767
                         PO<sub>5</sub>
91
     Cw*1402
                7769
                                ,,,,,,69QRQT,,,,77TVS,,,,,,,,,219W,,,,
                                ,,21H,,,,65QNR,,69QRQT,,,,77TVN,,,,94II,,,,
92
     Cw*1502
                738
                         NEG
                                ......69QRQT,...,77TVS,,,,,,,,193LV,,,,,
93
                4305
                         POS
     Cw*1601
                                ......113YN,116F,143ISQ,.....184R,,270C,,,275KP,,
94
     Cw*1701
                798
                         NEG
                         NEG
                                ......219W...275KP...
95
     Cw*1802
                1099
```

These are the eplets on HLA-C alleles of donor and the panel Cw*1203 has no mismatched eplets for this patient
One or more eplets on donor's Cw*0102 must react with antibody
Any reactivity with 65QNR of donor's Cw*0701?

Example of Luminex Screen for Antibodies Specific for HLA-C (4)

```
HLA-C Type
                Cw*0602
     Patient
     Patient
                Cw*0702
     Imm Donor Cw*0102 ,1C,6K,,,,,69QRQT,,,,77TVS,,,,,,,,,,219W,,,,,
     Imm Donor Cw*0701 .....65QNR.....
       Cut Off
                  1400
                         RX
                                Mismatched Eplets
Bead Allele
                   MFI
     NegCont
                   880
                                PosCont
                  12591
83
                  9850
                                ,1C,6K,.....69QRQT,....77TVS,......219W,....
     Cw*0102
                                ,,21H,,,,,,69QRQT,,,,,77TVN,,,,,,,,,,,,,211T,,,,,
                  1054
                         NEG
84
     Cw*0202
     Cw*0302
                  2118
                         POS
                                ,,21H,,,,,69QRQT,,,,,77TVS,,,,,94II,,,,,,163LW,173K,,,219W,,,,,
98
                                ,,21H,,,,,,69QRQT,,,,,77TVS,,,,,94II,,,,,,,,163LW,173K,,,219W,,,,
                         POS
97
                  5498
     Cw*0303
                                ,,21H,,,,,,69QRQT,,,,,77TVS,,,,,94II,,,,,,,163LW,173K,,,219W,,,,,
                  4991
                         POS
99
     Cw*0304
                                ,,17WR,,,,,,,,,,,113YN,116F,,,,,,219W,,,275KP,,
85
     Cw*0401
                  1393
                         NEG
86
                         NEG
                                ...35Q...46QGE....69QRQT.....77TVN.......113YN.116F.138K......177KT......275GP..
     Cw*0501
                  1330
                         SELF
87
                   813
     Cw*0602
                                .....
                   624
                         SELF
88
     Cw*0702
                                ..35Q...46QGE....69QRQT.....77TVS.......113YN,116F.....152RT..177KT......275GP...
                         POS
     Cw*0801
89
                  2465
     Cw*1203
                         NEG
90
                   767
                                .....
                         PO<sub>5</sub>
                                ,,,,,69QRQT,,,,77TVS,,,,,,,,,,,,,,219W,,,,,
91
                  7769
     Cw*1402
92
                         NEG
                                ,,21H,,,,,65QNR,,69QRQT,,,,77TVN,,,,94II,,,,,,,,,,
     Cw*1502
                   738
                                ......69QRQT,,,,77TVS,,,,,,,,,193LV,,,,,
93
                  4305
                         POS
     Cw*1601
                         NEG
                                ......113YN,116F,143ISQ,.....184R,,270C,,275KP,.
94
                   798
     Cw*1701
                         NEG
                                ,,,,,,,,,,,,,,,113YN,116F,,,,,,,219W,,,275KP,,
                  1099
95
     Cw*1802
```

No reactivity with 65QNR of donor's Cw*0701

No reactivity with the eplets of the negative alleles
Cw*0202, Cw*0401, Cw*0501, Cw*1502, Cw*1701 and Cw*1801
Record these negative alleles in the HLAMatchmaker program

Example of Luminex Screen for Antibodies Specific for HLA-C (5)

```
HLA-C Type
             Cw*0602
    Patient
    Patient
             Cw*0702
    Imm Donor Cw*0102 ,1C,6K,.....69QRQT,...,77TVS,.......219W,....
    Imm Donor Cw*0701 ,,,,,,65QNR,,,,,,,,,,,,,,,,,,,
      Cut Off 1400
Bead Allele
             MFI
                    RX
                          Mismatched Eplets
                                                                                 Eplets on Reactive Alleles
    NegCont
             880
                          .......
2
    PosCont
             12591
                         .1C.6K......69QRQT.....77TVS........219W.....
                                                                                 ,1C,6K,......<mark>77TVS</mark>,.....
83
    Cw*0102
             9850
84
    Cw*0202
             1054
                          ..21H......69QRQT.....77TVN.............211T.....
                                                                                 ,,21H,,,,,,69QRQT,,,,,77TVS,,,,,94II,,,,,,,163LW,173K,,,219W,,,,
98
    Cw*0302
             2118
                                                                                 ......163LW,173K,
                          ...21H......69QRQT.....77TVS.....94II.........163LW.173K...219W.....
                                                                                 97
    Cw*0303
             5498
                          ..21H......69QRQT.....77TVS.....94II........163LW.173K...219W.....
                                                                                 ,,,,,,,163LW,173K...
99
    Cw*0304
             4991
                          ,,17WR,,,,,,,,,,113YN,116F,,,,,,,219W,,,275KP,
85
    Cw*0401
             1393
                          ..35Q...46QGE....69QRQT.....77TVN,......113YN,116F,138K,...,177KT,...,2<sup>T</sup>,.....
86
    Cw*0501
             1330
                    NEG
                    SELF
87
    Cw*0602
             813
                          .....
                    SELF
88
    Cw*0702
             624
                          POS
89
    Cw*0801
             2465
90
    Cw*1203
             767
                    NEG
                          .....
                                                                                 .....
                          ,,,,,,69QRQT,,,,77TVS,,,,,,,,219W,,,,
91
    Cw*1402
             7769
                                                                                 ..21H....65QNR..69QRQT....77TVN....94II.....
92
    Cw*1502
             738
                    NEG
                                                                                 .....
                          ......69QRQT....77TVS.......193LV.....
93
    Cw*1601
             4305
                                                                                 ,,,,,,,,,,,<mark>77TV$</mark>,,,,,,,,,,,<u>1</u>93LV,,,,,
                         ......113YN,116F,143ISQ......184R,,270C,,,275KP,
94
    Cw*1701
             798
                    NEG
                         ......219W.,.275KP.,
95
    Cw*1802
             1099
                    NEG
                                                                                 .....
```

The 77TVS eplet of donor's Cw*0102 is present on all reactive alleles 77TVS is an unacceptable mismatch

Example of Luminex Screen for Antibodies Specific for HLA-C (6)

HLA-C Type
Patient Cw*0602
Patient Cw*0702

Imm Donor Cw*0102,1C,6K,,,,,,69QRQT,,,,,77TVS,,,,,,,,,,219W,,,,,

Imm Donor Cw*0701 ,,,,,,65QNR,,,,,,,,,,,,,,,,,,

	Cut Off	1400			
Be	ad Allele	MFI	RX	Mismatched Eplets	Eplets on Reactive Alleles
1	NegCont	088			
2	PosCont	12591			
83	Cw*0102	9850	IMM	,1C,6K,,,,,,69QRQT,,,,,77TVS,,,,,,,,,219W,,,,,	,1C,6K,,,,,, <mark>77TV\$</mark> ,,,,,,,
84	Cw*0202	1054	NEG	,,21H,,,,,,69QRQT,,,,,77TVN,,,,,,,,,,211T,,,,,	
98	Cw*0302	2118	POS	,,21H,,,,,,69QRQT,,,,,77TVS,,,,,94II,,,,,,,163LW,173K,,,219W,,,,	,,,,,,,,,,,,,,,,,,,,,,163LW,173K,,
97	Cw*0303	5498	POS	,,21H,,,,,,69QRQT,,,,,77TVS,,,,,94II,,,,,,,163LW,173K,,,219W,,,,	,,,,,,,,,,,,,,,,,,,,,,163LW,173K,,
99	Cw*0304	4991	POS	,,21H,,,,,,69QRQT,,,,,77TVS,,,,,94II,,,,,,,163LW,173K,,,219W,,,,	,,,,,,,,,,,,,,,,,,,,,,163LW,173K,,
85	Cw*0401	1393	NEG	,,17WR,,,,,,,,,,,113YN,116F,,,,,,219W,,,275KP,,	
86	Cw*0501	1330	NEG	,,35Q,,,46QGE,,,,69QRQT,,,,,77TVN,,,,,,113YN,116F,138K,,,,,,177KT,,,,,,2	!
87	Cw*0602	813	SELF		
88	Cw*0702	624	SELF		
89	Cw*0801	2465	POS	,,35Q,,,46QGE,,,,69QRQT,,,,,77TVS,,,,,,113YN,116F,,,,,152RT,,177KT,,,,,	:,,,,,,,,,, <mark>77TV\$</mark> ,,,,,,,,,152RT,,,,,,,
90	Cw*1203	767	NEG		
91	Cw*1402	7769	POS	,,,,,,69QRQT,,,,,77TVS,,,,,,,,,,219W,,,,,	,,,,,,,,,, <mark>77TV\$</mark> ,,,,,,,,,,,
92	Cw*1502	738	NEG	,,21H,,,,,65QNR,,69QRQT,,,,,77TVN,,,,,94II,,,,,,,,,,	
93	Cw*1601	4305	POS	,,,,,,,69QRQT,,,,,77TVS,,,,,,,,,,193LV,,,,,	,,,,,,,,,, <mark>77TV\$</mark> ,,,,,,,,,,193LV,,,,,
94	Cw*1701	798	NEG	,,,,,,,,,,,,,113YN,116F,143ISQ,,,,,,184R,,270C,,,275KP,,	
95	Cw*1802	1099	NEG	,,,,,,,,,,,,113YN,116F,,,,,,,,219W,,,275KP,,	

Acceptable Alleles

Cw*0202 *0401*0403*0404*0405*0501*0602*0603*0604*0701*0702*0704*0706*0707*0710*1202*1203*1204*1502*1503*1505*1506*1509*1701*1801

Eplet Unacceptable Alleles

77TVS <u>B*4601</u>Cw*0102*0103*0302*0303*0304*0305*0306*0310*0801*0802*0803*0804*1402*1403*1601*1604